SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavir/r IN Race/Gender HIV+ Patients Randomized to TDM or SoC
Public ClinicalTrials.gov record NCT00440271. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavi/r IN Race/Gender HIV+ Patients Randomized to Therapeutic Drug Monitoring or Standard of Care
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary purpose of this study is to: 1. Demonstrate the safety and efficacy of tipranavir/ritonavir (TPV/r) among a racially diverse HIV+ population (males and females) who are three-class (nucleoside reverse transcriptase inhibitor (NRTI), non-nucleoside reverse transcriptase inhibitor (NNRTI), and protease inhibitor (PI)) experienced with documented resistance to more than one PI. 2. Determine pharmacokinetic data in this racially and gender diverse population. 3. Determine the potential utility of using therapeutic drug monitoring (TDM) in improving efficacy outcomes.
Study identification
- NCT ID
- NCT00440271
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 33 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 31, 2007
- Primary completion
- Sep 30, 2008
- Completion
- Not listed
- Last update posted
- Jun 26, 2014
Started 2007
United States locations
- U.S. sites
- 16
- U.S. states
- 10
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1182.98.033 Boehringer Ingelheim Investigational Site | Washington D.C. | District of Columbia | — | — |
| 1182.98.018 Boehringer Ingelheim Investigational Site | Clearwater | Florida | — | — |
| 1182.98.014 Boehringer Ingelheim Investigational Site | Fort Lauderdale | Florida | — | — |
| 1182.98.041 Boehringer Ingelheim Investigational Site | Orlando | Florida | — | — |
| 1182.98.004 Boehringer Ingelheim Investigational Site | Decatur | Georgia | — | — |
| 1182.98.002 Boehringer Ingelheim Investigational Site | Kansas City | Missouri | — | — |
| 1182.98.016 Boehringer Ingelheim Investigational Site | New York | New York | — | — |
| 1182.98.026 Boehringer Ingelheim Investigational Site | New York | New York | — | — |
| 1182.98.034 Boehringer Ingelheim Investigational Site | Stony Brook | New York | — | — |
| 1182.98.040 Boehringer Ingelheim Investigational Site | Huntersville | North Carolina | — | — |
| 1182.98.006 Boehringer Ingelheim Investigational Site | Akron | Ohio | — | — |
| 1182.98.007 Boehringer Ingelheim Investigational Site | Cincinnati | Ohio | — | — |
| 1182.98.020 Boehringer Ingelheim Investigational Site | Oklahoma City | Oklahoma | — | — |
| 1182.98.029 Boehringer Ingelheim Investigational Site | Philadelphia | Pennsylvania | — | — |
| 1182.98.023 Boehringer Ingelheim Investigational Site | Austin | Texas | — | — |
| 1182.98.009 Boehringer Ingelheim Investigational Site | Houston | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 14 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00440271, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 26, 2014 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00440271 live on ClinicalTrials.gov.